Back to top
more

ObsEva SA (OBSV)

(Delayed Data from NSDQ)

$13.89 USD

13.89
12,706

-0.12 (-0.86%)

Updated May 3, 2019 04:13 PM ET

After-Market: $13.76 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

[OBSV]

Reports for Purchase

Showing records 1 - 20 ( 170 total )

Industry: Medical - Biomedical and Genetics

Record: 1

02/24/2023

Company Report

Pages: 4

NASDAQ De-Listing Planned; Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

09/28/2022

Company Report

Pages: 5

Restructuring Initiatives Reduce Operating Expenses; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

08/30/2022

Company Report

Pages: 5

Linzagolix Approvability Issues; Restructuring; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

06/21/2022

Company Report

Pages: 5

Linzagolix Wins European Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

05/23/2022

Company Report

Pages: 5

Linzagolix Edges Closer to Approval; 1Q22 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

04/25/2022

Company Report

Pages: 5

Linzagolix Positive European Opinion Received; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

03/28/2022

Company Report

Pages: 5

Additional EDELWEISS Data Released; 2021 Financials; Lowering PT to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

02/07/2022

Company Report

Pages: 4

Linzagolix European Approval Timeline Extension; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

01/10/2022

Company Report

Pages: 6

Linzagolix EDELWEISS 3 Pivotal Trial Data; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

12/17/2021

Company Report

Pages: 4

Linzagolix Positive European Opinion Received; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

12/14/2021

Company Report

Pages: 5

More Linzagolix Clinical Data Presented; New Finance Chief; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

11/29/2021

Company Report

Pages: 5

Linzagolix Application Accepted; 3Q21 Financials; Lowering PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

10/10/2021

Industry Report

Pages: 13

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

10/09/2021

Daily Note

Pages: 4

Emerging Pharmaceuticals - Dropping Coverage

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OBSV

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

09/17/2021

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

09/17/2021

Company Report

Pages: 6

Linzagolix NDA Submitted; Multiple Catalysts Ahead in Q4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

09/15/2021

Company Report

Pages: 5

Linzagolix New Drug Application for Uterine Fibroids Submitted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

09/01/2021

Company Report

Pages: 7

Corporate Update Ahead of Upcoming Catalysts

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 20

08/09/2021

Company Report

Pages: 5

Key Linzagolix Milestones Imminent; 2Q21 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party
// eof